GlassScriptPhysician profile
Mohini Gurme
NPI 1316173156
$12,972.42
in general payments reported to CMS, 2019-2025
63 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,029 · 2020: $1,863 · 2021: $2,401 · 2022: $1,808 · 2023: $1,931 · 2024: $1,296 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,869.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,764.53 | 2021-2025 | |
| Allergan, INC. | $874.82 | 2019-2022 | |
| Lilly USA, LLC | $676.67 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Eisai INC. | $551.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $487.59 | 2019-2024 | |
| Emd Serono, INC. | $425.73 | 2019-2023 | Mavenclad |
| Sk Life Science, INC. | $425.02 | 2020-2025 | |
| Kyowa Kirin, INC. | $370.61 | 2019-2025 | Nourianz |
| Amgen INC. | $355.38 | 2019-2022 | |
| Ucb, INC. | $319.49 | 2019-2025 | Nayzilam, Briviact |
| Pfizer INC. | $286.44 | 2019-2025 | |
| Lundbeck LLC | $286.28 | 2019-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $283.93 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $281.02 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $273.91 | 2019-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohini Gurme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.